Atopic dermatitis is a dermatitis that is chronic and inflammatory and that affects mainly babies and children, but can appear at any time in life. It is a pathology that is permanently increasing in industrialized countries.
This chronic disorder is characterized by alternative inflammatory outbreaks and remission periods. Many elements are typical of atopic dermatitis: a typical dermal xerosis over which allergens cause an eczema reaction.
In children, it shows mainly through insomnia, and frequent awakenings at night, that causes important problems in the parent-child relationship. Children are often nervousand irritable, which makes the treatment more delicate and complex.
In adults, the psychological impact may be greater, including important depressive syndromes.
Atopic dermatitis tends to appear in children between the ages of 3 and 6 months in the form of eczema areas with irregular borders, with more or less weeping, appearing mainly on the face, the limbs, first on the extensor surface and then on the joints, the lower back and the hands.
An essential element is skin dryness, which is permanent during atopic dermatitis, and more difficult to assess when the weather is hot and humid. This xerosis results in intense pruritus which strengthens scratching lesions and secondary infections. Most important forms include insomnia.
The aim is therefore to provide a treatment that allows:
> To recover the barrier function in order to limit skin dryness and the penetration of allergens
> To recover the skin ecosystem by checking the inflammatory response and preventing the development of pathogenic flora
> To give immediate and durable relief to improve patients’ comfort and their environment.
Based on these criteria, Noreva laboratories have launched a line called Xerodiane+®.